193 related articles for article (PubMed ID: 30284649)
1. The use of radiofrequency ablation in pancreatic cancer in the midst of the dawn of immuno-oncology.
Reccia I; Kumar J; Habib N; Sodergren M
Med Oncol; 2018 Oct; 35(12):151. PubMed ID: 30284649
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma.
Alemi F; Alseidi A; Scott Helton W; Rocha FG
Curr Probl Surg; 2015 Sep; 52(9):362-98. PubMed ID: 26363649
[No Abstract] [Full Text] [Related]
3. [Pancreatic cancer- a curable disease].
Limani P; Samaras P; Lesurtel M; Graf R; DeOliveira ML; Petrowsky H; Clavien PA
Praxis (Bern 1994); 2015 Apr; 104(9):453-60. PubMed ID: 25900693
[TBL] [Abstract][Full Text] [Related]
4. Immunological combination treatment holds the key to improving survival in pancreatic cancer.
Sodergren MH; Mangal N; Wasan H; Sadanandam A; Balachandran VP; Jiao LR; Habib N
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2897-2911. PubMed ID: 32748119
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous ablation of pancreatic cancer.
D'Onofrio M; Ciaravino V; De Robertis R; Barbi E; Salvia R; Girelli R; Paiella S; Gasparini C; Cardobi N; Bassi C
World J Gastroenterol; 2016 Nov; 22(44):9661-9673. PubMed ID: 27956791
[TBL] [Abstract][Full Text] [Related]
6. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
7. Radiofrequency ablation of liver metastasis in patients with locally controlled pancreatic ductal adenocarcinoma.
Park JB; Kim YH; Kim J; Chang HM; Kim TW; Kim SC; Kim PN; Han DJ
J Vasc Interv Radiol; 2012 May; 23(5):635-41. PubMed ID: 22525021
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma].
Kawaida H; Fujii H
Nihon Rinsho; 2015 Mar; 73 Suppl 3():181-5. PubMed ID: 25857011
[No Abstract] [Full Text] [Related]
9. Strategies to improve the outcome in locally advanced pancreatic cancer.
Späth C; Nitsche U; Müller T; Michalski C; Erkan M; Kong B; Kleeff J
Minerva Chir; 2015 Apr; 70(2):97-106. PubMed ID: 25658301
[TBL] [Abstract][Full Text] [Related]
10. Local ablation of pancreatic tumors: State of the art and future perspectives.
Granata V; Grassi R; Fusco R; Belli A; Palaia R; Carrafiello G; Miele V; Grassi R; Petrillo A; Izzo F
World J Gastroenterol; 2021 Jun; 27(23):3413-3428. PubMed ID: 34163121
[TBL] [Abstract][Full Text] [Related]
11. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
12. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy.
Smith C; Zheng W; Dong J; Wang Y; Lai J; Liu X; Yin F
World J Gastroenterol; 2022 Jul; 28(27):3297-3313. PubMed ID: 36158269
[TBL] [Abstract][Full Text] [Related]
14. Irreversible electroporation: a novel therapy for stage III pancreatic cancer.
Weiss MJ; Wolfgang CL
Adv Surg; 2014; 48():253-8. PubMed ID: 25293620
[No Abstract] [Full Text] [Related]
15. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
16. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
17. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].
Ye C; Zheng L; Yuan CH
Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387
[TBL] [Abstract][Full Text] [Related]
18. The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy.
Hilmi M; Delaye M; Muzzolini M; Nicolle R; Cros J; Hammel P; Cardot-Ruffino V; Neuzillet C
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1129-1142. PubMed ID: 37866368
[TBL] [Abstract][Full Text] [Related]
19. Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma.
Swords DS; Mulvihill SJ; Firpo MA; Scaife CL
JAMA Oncol; 2018 Aug; 4(8):1129-1130. PubMed ID: 30003235
[TBL] [Abstract][Full Text] [Related]
20. Elastography of pancreatic ductal adenocarcinoma following EUS-guided radiofrequency ablation (with video).
Mazzawi T; Chaiyapo A; Kongkam P; Ridtitid W; Rerknimitr R
Arab J Gastroenterol; 2020 Jun; 21(2):128-131. PubMed ID: 32430256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
